According to a new report Europe Veterinary Oncology Market, published by KBV research, the Europe Veterinary oncology Market would witness market growth of 12.8% CAGR during the forecast period (2020-2026).
The Germany market is the major revenue generating regions within the Europe Surgery Market by Country in 2019, growing at a CAGR of 13 % during the forecast period. The UK market is witnessing a CAGR of 12.7% during (2020 - 2026). Additionally, The France market is poised to grow at a CAGR of 15.2% during (2020 - 2026).
The Canine market dominated the France Veterinary Oncology Market by Animal Type in 2019, thereby, achieving a market value of $12.9 million by 2026, growing at a CAGR of 13.9 % during the forecast period. The Feline market is expected to witness a CAGR of 14.8% during (2020 - 2026).
The Lymphoma market dominated the Spain Veterinary Oncology Market by Cancer Type in 2019, growing at a CAGR of 12.4 % during the forecast period. The Mast Cell Cancer market would exhibit a CAGR of 12.9% during (2020 - 2026). The Mammary & Squamous Cell Cancer market is projected to grow at a CAGR of 14.4% during (2020 - 2026).
Structural Insights: https://www.kbvresearch.com/europe-veterinary-oncology-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.
By Animal Type
By Therapy
By Cancer Type
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
